Results 221 to 230 of about 64,409 (290)

Exercise‐specific plasma proteomic signatures in racehorses: Candidates for training adaptation and peak load monitoring

open access: yesEquine Veterinary Journal, EarlyView.
Abstract Background Racehorses undergo profound physiological changes with training and competition, but current biomarkers inadequately capture the complex molecular dynamics of exercise. This study aimed to identify novel plasma biomarkers of training adaptation and peak load using high‐throughput proteomics.
Jowita Grzędzicka   +4 more
wiley   +1 more source

Fluorescent Labeling of Small Extracellular Vesicles (EVs) Isolated from Conditioned Media.

open access: yesBio Protoc, 2022
Santelices J   +4 more
europepmc   +1 more source

Enhancing Optogenetics‐Based Cancer Therapy Via Nanotechnology

open access: yesExploration, EarlyView.
Nanotechnology enhances optogenetics‐based cancer therapy through improved delivery systems and non‐invasive optical regulation. It further enables precise and programmable control of optogenetic living therapeutics for localized antitumor responses.
Honggang Shen   +8 more
wiley   +1 more source

CCL26‐Mediated Modulation of Endothelial Secretome by Hypoxia‐Induced Tumor‐Derived Exosomes Enhances Metastatic Progression in Head and Neck Cancer

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Tumor cells adapt to hypoxia by releasing hiTDExs enriched with bioactive molecules that modulate endothelial behavior and promote tumor progression. This study aimed to characterize how hypoxia‐induced HNSCC exosomes reshape the endothelial secretome and contribute to metastatic potential.
Ozel Capik   +6 more
wiley   +1 more source

Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due to its asymptomatic progression, late‐stage diagnosis, and treatment resistance. Efforts in early detection have centered on identifying imaging features and liquid biopsy biomarkers capable of detecting PDAC and its high‐grade precursors before clinical symptoms ...
Christine Worthington   +105 more
wiley   +1 more source

Post‐Translational Modifications of Key Proteins in Hematologic Malignancies: Carcinogenic Mechanisms, Biomarker Potential, and New Therapeutic Strategies

open access: yesiLABMED, EarlyView.
This article reviews the pivotal role of post‐translational modifications of proteins in the development and progression of hematologic malignancies, and explores their clinical translation potential as novel biomarkers and therapeutic targets. ABSTRACT Post‐translational modifications (PTMs) of proteins have emerged as critical regulators in the ...
Yuxuan Han   +6 more
wiley   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

open access: yesiMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy